Literature DB >> 6799573

Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors.

K Yoshizaki, T Nakagawa, T Kaieda, A Muraguchi, Y Yamamura, T Kishimoto.   

Abstract

The proliferation and differentiation of human leukemic B cells (B-CLL cells) with anti-Ig and T cell-derived helper factors are described. Stimulation of B-CLL cells with anti-Ig and T helper factors could induce proliferation as well as differentiation into IgM- and IgG-producing cells. Neither anti-Ig nor T helper factors alone could induce any proliferation and/or differentiation of B-CLL cells. Not only whole molecules of anti-Ig but also F(ab')2 fragments could induce proliferation and differentiation of B-CLL cells in the presence of T helper factors, but monovalent Fab' fragments were not effective. Induction of both IgM and IgG with the same idiotype was confirmed by immunofluorescent and SDS-PAGE analysis. By employing an IL 2-dependent cytotoxic T cell line and a TRF-responsive B cell line, T cell factors were separated into a fraction with IL2 activity but no TRF activity and a fraction with TRF activity but no IL 2 activity by chromatofocusing. Anti-Ig and IL 2 fraction could induce proliferation of B-CLL cells, but TRF fraction was not effective for the induction of proliferation in anti-IG-stimulated cells. For IgM and IgG production, anti-Ig and both IL 2 and TRF fractions were required. Depletion of IL 2 fraction in the first 2 days' culture inhibited Ig production, whereas the absence of TRF fraction in the first 2 days did not show any inhibitory effect on Ig production.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6799573

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications.

Authors:  J Braun; A Saxon; R Wall; S L Morrison
Journal:  West J Med       Date:  1992-08

2.  Differential mechanism for differentiation into immunoglobulin-secreting cells in human resting B lymphocyte subsets isolated on the basis of cell density.

Authors:  N Suzuki; Y Ueda; T Sakane
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

3.  B-cell maturation in chronic lymphocytic leukaemia. IV. T-cell-dependent activation of leukaemic B cells by staphylococcal enterotoxin 'superantigens'.

Authors:  X Duan; C Nerl; O Janssen; D Kabelitz
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

Review 4.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

Authors:  K Yoshizaki; N Nishimoto; M Mihara; T Kishimoto
Journal:  Springer Semin Immunopathol       Date:  1998

5.  NDA3: a differentiation antigen associated with the receptor for B cell growth factor.

Authors:  N Suciu-Foca; C Rohowsky-Kochan; S J Rosochacki; E Cristea; J D Cai; E Reed; D W King
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

6.  Production of a monoclonal antibody useful in the molecular characterization of murine T-cell-replacing factor/B-cell growth factor II.

Authors:  N Harada; T Takahashi; M Matsumoto; T Kinashi; J Ohara; Y Kikuchi; N Koyama; E Severinson; Y Yaoita; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

7.  Models and mechanisms for signal transduction in B cells.

Authors:  C A Pennell; D W Scott
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

8.  Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis.

Authors:  K Nakanishi; T R Malek; K A Smith; T Hamaoka; E M Shevach; W E Paul
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

9.  Interleukin-5 (IL-5) and IL-6 define two molecularly distinct pathways of B-cell differentiation.

Authors:  T D Randall; F E Lund; J W Brewer; C Aldridge; R Wall; R B Corley
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

10.  Review of tocilizumab in the treatment of rheumatoid arthritis.

Authors:  Yasuaki Okuda
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.